Curaleaf Holdings (CURLF) Change in Accured Expenses (2019 - 2024)
Curaleaf Holdings (CURLF) posted quarterly Change in Accured Expenses of -$178.1 million for Q4 2024, down 1047.84% year-over-year from $18.8 million in Q1 2024, and down 514.81% quarter-over-quarter from $42.9 million in Q3 2024.
Curaleaf Holdings (CURLF) Change in Accured Expenses (2019 - 2024) Analysis & Trends
Curaleaf Holdings' Change in Accured Expenses history runs 6 years deep, the most recent figure standing at -$178.1 million for Q4 2024.
- In Q4 2024, Change in Accured Expenses fell 1047.84% year-over-year to -$178.1 million; the TTM figure through Dec 2024 stood at -$157.1 million (down 481.58% YoY), while the FY2025 annual figure was $147.9 million, up 24.91% from the prior year.
- Change in Accured Expenses for Q4 2024 stood at -$178.1 million, down from $42.9 million in the prior quarter.
- The five-year high for Change in Accured Expenses was $60.7 million in Q4 2021, with the low at -$178.1 million in Q4 2024.
- The 5-year median for Change in Accured Expenses is -$167500.0 (2021), against an average of -$1.3 million.
- The sharpest annual moves came in 2021 and 2022: Change in Accured Expenses jumped 3430.68% in 2021, then tumbled 6757.89% in 2022.
- Curaleaf Holdings' Change in Accured Expenses stood at -$1.8 million in 2020, then surged by 3430.68% to $60.7 million in 2021, then retreated by 4.48% to $58.0 million in 2022, then slumped by 126.77% to -$15.5 million in 2023, then slumped by 1047.84% to -$178.1 million in 2024.
- Business Quant data shows CURLF's Change in Accured Expenses at -$178.1 million in Q4 2024, $42.9 million in Q3 2024, and -$15.5 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 82.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 142.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -219.00 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | -4.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -8.50 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Curaleaf Holdings | 2.51 Bn | 2.42 Bn | 169.91 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -178.11 Mn |
| Dec 31, 2024 | -178.11 Mn |
| Sep 30, 2024 | 42.94 Mn |
| Sep 30, 2024 | 42.94 Mn |
| Dec 31, 2023 | -15.52 Mn |
| Dec 31, 2023 | -15.52 Mn |
| Sep 30, 2023 | -6.46 Mn |
| Sep 30, 2023 | -6.46 Mn |
| Dec 31, 2022 | 57.96 Mn |
| Dec 31, 2022 | 57.96 Mn |
| Sep 30, 2022 | 5.19 Mn |
| Sep 30, 2022 | 5.19 Mn |
| Jun 30, 2022 | -6.33 Mn |
| Jun 30, 2022 | -6.33 Mn |
| Mar 31, 2022 | -430,000.00 |
| Mar 31, 2022 | -430,000.00 |
| Dec 31, 2021 | 60.69 Mn |
| Dec 31, 2021 | 60.69 Mn |
| Sep 30, 2021 | 23.27 Mn |
| Sep 30, 2021 | 23.27 Mn |